Clinical Trials Logo

Filter by:
NCT ID: NCT04857996 Completed - Clinical trials for Diabetic Macular Edema (DME)

Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)

Start date: June 25, 2021
Phase: Phase 2
Study type: Interventional

This study is intended to assess the exposure, safety, biological activity, and durability of UBX1325, a phosphate pro-drug, and its active parent molecule (UBX0601) following a single intravitreal (IVT) injection of UBX1325 in patients with diabetic macular edema (DME).

NCT ID: NCT04857918 Completed - Physical Activity Clinical Trials

Assessing the Feasibility and Acceptability of a Social Identity Informed Virtual Running Group Program

Start date: April 23, 2021
Phase: N/A
Study type: Interventional

The STRIDE Pilot Trial is a randomized controlled pilot trial that will utilize social identity informed virtual running groups to support underactive undergraduate students' well-being and exercise behaviour. The main outcomes of this study are to determine whether the intervention is feasible and acceptable to conduct as a full-scale efficacy trial. Secondary outcomes of interest include changes in participants' exercise identity, exercise behaviour, perceived social support, and well-being. Participants' perceived social identification with their running group will also be assessed at the end of the study.

NCT ID: NCT04857814 Completed - Cystic Fibrosis Clinical Trials

Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Diseases

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Lung diseases are one of the most common causes of emergency room visits. There are very few tools that are able to predict which patients will have a worsening or increasing severity of their condition. There are also limited ways to check the health of patients with respiratory conditions at home and during the time between medical appointments. The ADAMM-RSMTM device records heart rate, breathing rate, temperature, cough and activity while wearing it. This study will test participants willingness to wear the device and perform ongoing monitoring to assess the possibility to predict the onset and increases in severity of their lung conditions.

NCT ID: NCT04856930 Completed - Clinical trials for Hidradenitis Suppurativa

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa

Start date: July 7, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of Imsidolimab (ANB019) in Subjects with Hidradenitis Suppurativa

NCT ID: NCT04856917 Completed - Acne Vulgaris Clinical Trials

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Start date: May 15, 2021
Phase: Phase 2
Study type: Interventional

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

NCT ID: NCT04856904 Completed - Acne Vulgaris Clinical Trials

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

START
Start date: May 28, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

NCT ID: NCT04856072 Completed - Alzheimer Disease Clinical Trials

Deep Brain Stimulation in Alzheimer's Disease: Biomarkers and Dose Optimization

Start date: December 19, 2014
Phase: N/A
Study type: Interventional

Title: Deep Brain Stimulation of the Fornix in Alzheimer's Disease: Investigating clinical and imaging biomarkers and dose optimization Objective: To evaluate the influence of deep brain stimulation in Alzheimer's Disease (AD)on markers of AD pathology in cerebrospinal fluid (CSF) and on neuroimaging with positron emission tomography (PET) and to optimize electrical stimulation parameters. Population size: Twelve (12) patients will be recruited and enrolled in this study. Study design: This is a prospective, open-label trial designed to study the effect of brain stimulation on CSF and brain amyloid pathology in AD. In addition, patients will undergo neuropsychological testing at various stimulation settings to help determine optimal stimulation parameters. Study duration: Patients will complete screening and baseline assessments before undergoing DBS implantation surgery, after which they will be followed-up for 12 months.

NCT ID: NCT04855578 Completed - Polypharmacy Clinical Trials

Deprescription of Gabapentinoids in Medical Inpatients

GABA-WHY
Start date: May 28, 2021
Phase: N/A
Study type: Interventional

In this trial, investigators will distribute educational brochures with information about the deprescription of gabapentinoids (gabapentin and pregabalin) to inpatients in five medical wards spread across two tertiary-care hospitals in Montréal, Canada. This intervention will be supplemented by a brief information session for medical staff on the wards. This study aims to evaluate the effectiveness of this combined intervention on increasing gabapentinoid deprescription rates among study participants compared to control following hospital discharge.

NCT ID: NCT04855474 Completed - Healthy Clinical Trials

Protein Requirements in Male and Female Endurance Athletes

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

Protein is an essential macronutrient for post-exercise recovery through its ability to provide the amino acid building blocks that support increased rates of muscle and whole body protein synthesis. Despite the growing understanding of the importance of post-exercise protein in endurance athlete populations, the impact of sex and female menstrual cycle phase on protein metabolism is not fully understood. To date, no studies have examined protein requirements in female endurance trained athletes. The aim of the proposed study is to utilize the well-established IAAO method to determine protein requirements in endurance trained female and male athletes in a "real-world" and at-home setting.

NCT ID: NCT04854603 Completed - Clinical trials for Overweight and Obesity

Dairy Products With Reduced Sugar and Blood Glucose

Start date: September 2, 2021
Phase: N/A
Study type: Interventional

Dairy products represent an important food group in human nutrition as a source of calcium, protein, functional fats and low-glycaemic sugar lactose. While traditionally consumed natural milk and yogurt have low sugar content, many flavoured liquid dairy products such as chocolate milk, or fermented products such as yogurt have added sugar. Our recent studies have shown that the partial reduction of added sugar in chocolate milk and yogurt is not associated with any inferior sensory characteristics such as taste and pleasantness compared to their full-sugar counterparts. The current project will investigate whether the liquid dairy products with reduced sugar content (value-added products) have any benefits on blood glucose control in humans.